AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Spero Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00HXSJ1S1
1.11▼ 0.02 (-1.77%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
1.13
Day's Range
1.10 – 1.13
52-Week Range
1.08 – 3.08
Volume
316.2K
Avg Volume
719.1K
Share Statistics
Shares Outstanding
Employees
25
Exchange
XNAS
Listed
2017-11-02
Share count as of August 7, 2026

Spero Therapeutics, Inc. Common Stock (SPRO) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Spero Therapeutics, Inc. Common Stock (SPRO)
What is Spero Therapeutics, Inc. Common Stock's Market Cap?
Spero Therapeutics, Inc. Common Stock's Market Cap is $64.6M, based on as-reported figures from SEC (XBRL) filings.
What is Spero Therapeutics, Inc. Common Stock's Enterprise Value?
Spero Therapeutics, Inc. Common Stock's Enterprise Value is $13.9M, based on as-reported figures from SEC (XBRL) filings.
What is Spero Therapeutics, Inc. Common Stock's Trailing P/E?
Spero Therapeutics, Inc. Common Stock's Trailing P/E is 8.8×, based on as-reported figures from SEC (XBRL) filings.
What is Spero Therapeutics, Inc. Common Stock's Price / Sales?
Spero Therapeutics, Inc. Common Stock's Price / Sales is 1.4×, based on as-reported figures from SEC (XBRL) filings.
What is Spero Therapeutics, Inc. Common Stock's EV / Revenue?
Spero Therapeutics, Inc. Common Stock's EV / Revenue is 0.3×, based on as-reported figures from SEC (XBRL) filings.
What is Spero Therapeutics, Inc. Common Stock's EV / EBITDA?
Spero Therapeutics, Inc. Common Stock's EV / EBITDA is 2.5×, based on as-reported figures from SEC (XBRL) filings.
What is Spero Therapeutics, Inc. Common Stock's Revenue (TTM)?
Spero Therapeutics, Inc. Common Stock's Revenue (TTM) is $47.0M, based on as-reported figures from SEC (XBRL) filings.
What is Spero Therapeutics, Inc. Common Stock's Net Income (TTM)?
Spero Therapeutics, Inc. Common Stock's Net Income (TTM) is $7.4M, based on as-reported figures from SEC (XBRL) filings.
What is Spero Therapeutics, Inc. Common Stock's EBITDA?
Spero Therapeutics, Inc. Common Stock's EBITDA is $6.0M, based on as-reported figures from SEC (XBRL) filings.
What is Spero Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Spero Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is 0.13, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · SPROAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Grant revenue
Collaboration revenue - related party
Collaboration revenue
Total revenues
YoY growth-100.0%-95.6%+174.5%-59.6%
Operating expenses:
Research and development
General and administrative
Restructuring
Total operating expenses
% of revenue—3021.7%24.0%245.5%
Loss from operations
% of revenue—-2921.7%76.0%-145.5%
Other income (expense):
Interest income
Other income (expense), net
Total other income, net
Net loss and comprehensive loss
% of revenue—-2791.9%76.3%-135.6%
Net loss per share attributable to common stockholders, basic
Net loss per share attributable to common stockholders, diluted